By Business/Source
Currency:AUD
2025/FY
Stock NameRevenueRatio
Development of invariant Natural Killer T (iNKT) cell platform for cancer treatment and its oral136K100.00%
By Country/Region
Currency:AUD
2025/FY
Stock NameRevenueRatio
Australia136K100.00%
